Notable Labs assists doctors in identifying personalized combinations of FDA-approved treatments for cancer patients. Notable is focused on individual patients and using existing treatments, they are exploring new indications of drugs and identifying mechanisms underlying cancer progression and drug resistance. Using robotic and modern data science, Notable is developing a scalable, iterative model that will turn individual treatment selection into a quantifiable problem.
Notable has formed several clinical trial partnerships with health centers and hospitals, including but not limited to:
- The University of Kansas Medical Center
- Orlando Health
- UHN Princess Margret Cancer Centre
- The University of Texas, MD Anderson Cancer Center
- UCSF Hellen Diller Family Comprehensive Cancer Center
Notable has published numerous cancer research studies with various organizations, many of which have been made available for public reading.
Timeline
Funding rounds
People
Hiroomi Tada, M.D., Ph.D.
Cheif Medical Officer
Kathryn Vanderlaag
Senior Director, Biology and Assay Development
Further reading
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study
Jenny L. Smith, Rhonda E. Ries, Tiffany Hylkema, Todd A Alonzo, Robert B Gerbing, Marianne T. Santaguida, Lisa Eidenschink Brodersen, Laura Pardo, Carrie L Cummings, Keith R Loeb, Quy Le, Suzan Imren, Amanda R Leonti, Alan S. Gamis, Richard Aplenc, E Anders Kolb, Jason E. Farrar, Timothy J. Triche, Cu Nguyen, Daoud Meerzaman, Michael R Loken, Vivian G. Oehler, Hamid Bolouri and Soheil Meshinchi
Web
Notable Labs lands $40M to expand AI-based cancer treatment tech
Amirah Al Idrus
Web
July 16, 2019